Alternate dosing of fingolimod in relapsing-remitting multiple sclerosis: A systematic review

Background: Fingolimod is approved in relapsing-remitting multiple sclerosis (RRMS) with the recommended dose of 0.5 mg daily. To tackle possible adverse events, some clinicians may reduce the dose of fingolimod, mainly in the alternate-day form. We systematically reviewed the literature for efficac...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghadiri, Fereshteh, Mirmosayyeb, Omid, Sahraian, Mohammad Ali, Moghadasi, Abdorreza Naser, Ghajarzadeh, Mahsa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Tehran University of Medical Sciences 2023
Materias:
Review Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460927/
https://www.ncbi.nlm.nih.gov/pubmed/38011360
http://dx.doi.org/10.18502/cjn.v22i2.13339

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460927/
https://www.ncbi.nlm.nih.gov/pubmed/38011360
http://dx.doi.org/10.18502/cjn.v22i2.13339

Ejemplares similares